Everolimus Tablets 0.5 mg (EVERENOLIMUS 0.5): Uses, Dosage, Side Effects & Precautions

 Everolimus Tablets 0.5 mg are used to help prevent the body from rejecting a transplanted organ, mainly a kidney or liver. EVERENOLIMUS 0.5 from Steris Healthcare is made for transplant teams and patients who need a low-strength, precisely adjustable dose. Everolimus belongs to the mTOR inhibitor class. Doctors usually prescribe it with a reduced dose of cyclosporine or tacrolimus and with corticosteroids. It is a specialist medicine and should only be started and adjusted by a transplant physician.

Why Is Everolimus Tablets 0.5 mg Important?

A transplanted organ is recognised by the immune system as foreign. Without lifelong immune suppression, rejection can damage or destroy the graft, and the patient may return to dialysis or face liver failure. Everolimus Tablets 0.5 mg lower this risk by calming the T-cell activity that drives rejection.

The 0.5 mg strength matters because everolimus has a narrow therapeutic window. Too little drug can allow rejection. Too much can raise the risk of infection, mouth ulcers, high cholesterol and kidney strain. Doctors check blood trough levels, usually aiming for about 3 to 8 ng/mL in transplant care, and then fine-tune the dose in small steps. A 0.5 mg tablet allows these small adjustments without splitting tablets. EVERENOLIMUS 0.5 is manufactured by Steris Healthcare, a WHO-GMP and ISO-certified manufacturer in Jaipur, which supports consistent quality for a medicine where accuracy matters.

Key Benefits of Everolimus Tablets 0.5 mg

What Are the Benefits of EVERENOLIMUS 0.5?

• Helps prevent acute rejection after kidney and liver transplantation
• Allows a lower dose of cyclosporine or tacrolimus, which may reduce calcineurin-inhibitor kidney toxicity
• Helps protect long-term graft function when used under specialist monitoring
• Offers a low 0.5 mg strength for gradual, level-guided dose adjustment
• Has antiproliferative action that may reduce graft vessel changes seen with chronic rejection
• Supports consistent day-to-day immune suppression when taken at the same times daily

Mechanism of Action

Everolimus binds to the intracellular protein FKBP-12. This complex then inhibits mTOR (mammalian target of rapamycin), a key regulator of cell growth. By blocking mTOR, everolimus stops T-lymphocytes from multiplying in response to interleukin-2 and other growth signals. Fewer activated T-cells means less attack on the transplanted organ. Because its pathway differs from that of calcineurin inhibitors, the two drug classes can be combined at lower doses.

Dosage Guidelines for Everolimus Tablets 0.5 mg

Dosing is strictly individual and set by the transplant team.

• Kidney transplant: the usual starting dose is 0.75 mg twice daily, started as soon as possible after surgery.
• Liver transplant: the usual starting dose is 1 mg twice daily, started about 30 days after surgery.
• Combinations: a 0.5 mg tablet is often used to build or adjust these doses.
• Monitoring: trough levels are checked about 4 to 5 days after any dose change.
• How to take it: swallow whole with water, at the same times each day, consistently with or without food. Do not crush, chew or stop suddenly.

Side Effects of Everolimus Tablets 0.5 mg

Common effects include:

• Swelling of the legs or ankles
• Nausea and constipation
• High blood pressure
• Headache and mouth ulcers
• Raised cholesterol or triglycerides
• Anaemia and urinary tract infections

Serious Side Effects of Everolimus Tablets 0.5 mg

Seek urgent medical help for:

• Fever, chills or other signs of serious infection
• Persistent cough or breathlessness, which may be non-infectious pneumonitis
• Reduced urine output, or blood or protein in the urine
• Swelling of the face, lips or tongue (angioedema)
• Poor wound healing or fluid collection around the wound
• Blood clotting problems in the transplanted kidney
• New-onset diabetes or very high blood sugar
• Unexplained lumps, or skin changes that suggest malignancy

Available Substitutes for Everolimus Tablets 0.5 mg

Other everolimus brands in 0.25 mg, 0.75 mg and 1 mg strengths exist, including originator brands such as Certican. Other immunosuppressants, such as tacrolimus, sirolimus or mycophenolate, work differently and are not direct substitutes. Never switch brands or molecules on your own, because small level changes can affect graft safety. Always consult your transplant physician first.

Precautions & Warnings with Using Everolimus Tablets 0.5 mg

• Avoid it in anyone allergic to everolimus, sirolimus or any tablet ingredient.
• Strong CYP3A4/P-gp inhibitors (ketoconazole, clarithromycin, ritonavir) raise levels. Inducers (rifampicin, St John’s wort) lower levels.
• Avoid grapefruit and grapefruit juice.
• Avoid live vaccines. Use sun protection, because immune suppression raises skin cancer risk.
• Use caution in liver impairment, as the dose may need reducing.
• Monitor kidney function, urine protein, lipids, blood counts and glucose regularly.
• Pregnancy: use only if clearly needed. Effective contraception is advised during treatment and for about 8 weeks after stopping.
• Tell your doctor about all medicines you take, including herbal products.

Conclusion

Everolimus Tablets 0.5 mg, supplied as EVERENOLIMUS 0.5 by Steris Healthcare, is a targeted mTOR-inhibitor therapy for preventing organ rejection. Its low strength supports careful, level-guided dosing, and it can help reduce calcineurin-inhibitor exposure. Used with regular blood monitoring and specialist supervision, it is an important part of long-term transplant care.